In a world increasingly focused on health and well-being, the healthcare industry stands at the forefront of innovation and growth. The demand for quality healthcare services continues to surge, driven by an aging population, advancements in medical technology, and a global emphasis on preventative care. Investing in strong healthcare stocks presents a compelling opportunity, offering the possibility of robust returns and long-term stability.
Here are three “Strong Buy” Healthcare stocks from Wall Street –
Lantheus Holdings, Inc. – SYM: LNTH
Recent Price: $56.40
Price Target: $96.63
Firms with Buy Rating: Jefferies, TD Cowen, JMP Securities
Description: Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
===
The 10 Best AI Stocks to Own NOW—Yours FREE
If you’ve been following the AI revolution, there’s a chance you can guess who’s #1 on my brand new list of the best AI stocks to own (if you are lucky, you may even own some shares of this powerhouse already). But I doubt you can guess who’s #3 on the list. (HINT: It delivers a technology that’s critical to the AI revolution and will soon be embedded in countless consumer products.)
Learn the names of all 10 stocks here. FREE.
===
ICON Public Limited Company – SYM: ICLR
Recent Price: $283.94
Price Target: $318.38
Firms with Buy Rating: Barclays, Jefferies, J.P. Morgan
Description: ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; and clinical research services, including biostatistics, clinical operations, clinical supplies management, covid-19, data management, decentralized & hybrid clinical solutions, endpoint adjudication services, interactive response technologies, investigator payments, medical affairs, medical writing and publishing, pharmacovigilance, and site and patient solutions. The company also provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. In addition, it offers commercial positioning, early phase, language, medical imaging, and strategic solutions, as well as clinical trial management, consulting, and contract staffing services. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
===
How Do You Feel About Your Financial Future?
Will the Fed’s experiments with a US digital dollar impact your savings?
NEW Digital Dollar Information Kit reveals what you need to know.
Get straightforward answers to uncomfortable questions about the rise of the Digital Dollar.
Yours FREE >>
===
Penumbra, Inc. – SYM: PEN
Recent Price: $256.49
Price Target: $295.86
Firms with Buy Rating: Piper Sandler, Wells Fargo, J.P. Morgan
Description: Penumbra, Inc., together with its subsidiairies, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, SENDit, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System, Lightning, and CAT RX brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and POD (Penumbra Occlusion Device) brand, as well as immersive 3D computer-based technology platform under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
